Target Information

Target General Infomation
Target ID
T60345
Target Name
T-cell surface glycoprotein CD3
Target Type
Clinical Trial
Disease Acute lymphoblastic leukemia; Acute myeloid lymphoma [ICD9:204.0, 556; ICD10: C91.0, C92.0]
Acute lymphoblastic leukemia [ICD9: 204.0, 556; ICD10: C91.0]
Non-hodgkin's lymphoma [ICD10: C85]
Type 1 diabetes [ICD9: 250; ICD10: E10]
BioChemical Class
Antigen
Drugs and Mode of Action
Drug(s) Blinatumomab Drug Info Approved Acute lymphoblastic leukemia [889388], [889412]
Otelixizumab Drug Info Phase 2 Type 1 diabetes [543149], [547674]
CD20Bi aATC Drug Info Phase 1 Non-hodgkin's lymphoma [544343]
MGD006 Drug Info Phase 1 Acute lymphoblastic leukemia; Acute myeloid lymphoma [544458], [889399]
Modulator Blinatumomab Drug Info [533123]
CD20Bi aATC Drug Info [544343]
MGD006 Drug Info [544458]
Otelixizumab Drug Info
References
Ref 543149(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8458).
Ref 544343CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma. Biol Blood Marrow Transplant. 2013 June; 19(6): 925-933.
Ref 544458A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML). J Immunother Cancer. 2014; 2(Suppl 3): P87.
Ref 547674Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018350)
Ref 889388ClinicalTrials.gov (NCT02013167) Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Ref 889399ClinicalTrials.gov (NCT02152956) Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS
Ref 889412ClinicalTrials.gov (NCT02393859) Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL
Ref 5331232014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
Ref 544343CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma. Biol Blood Marrow Transplant. 2013 June; 19(6): 925-933.
Ref 544458A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML). J Immunother Cancer. 2014; 2(Suppl 3): P87.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.